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The MHC class II-restricted antigen processing pathway generates peptide:MHC com-
plexes in the endocytic pathway for the activation of CD4+ T cells. Gamma-interferon-
inducible lysosomal thiol reductase (GILT) reduces protein disulfide bonds in the endocytic
compartment, thereby exposing buried epitopes for MHC class II binding and presentation.
T cell hybridoma responses and elution of MHC class II bound peptides have identified GILT-
dependent epitopes, GILT-independent epitopes, and epitopes that are more efficiently
presented in the absence of GILT termed GILT-prevented epitopes. GILT-mediated alter-
ation in the MHC class II-restricted peptidome modulatesT cell development in the thymus
and peripheral tolerance and influences the pathogenesis of autoimmunity. Recent studies
suggest an emerging role for GILT in the response to pathogens and cancer survival.
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INTRODUCTION
Protein disulfide bonds are common structural elements that
maintain the tertiary structure of proteins. Reduction of protein
disulfide bonds is an important step in MHC class II-restricted
processing and presentation for the activation of CD4+ T cells.
Disulfide bond reduction and the acidic pH found in the lysoso-
mal compartment destabilize the tertiary structure of proteins and
permit MHC class II binding to full-length proteins and protein
fragments (1, 2). Reduction also facilitates lysosomal proteolytic
digestion of antigens and generation of MHC class II binding
peptides (3). Multiple epitopes require disulfide bond reduction
for MHC class II-restricted presentation (3–7). The intracellular
reducing activity is primarily associated with lysosomes. Gamma-
interferon-inducible lysosomal thiol reductase (GILT) is the only
reductase known to be localized in this compartment. GILT is
synthesized as a 35 kDa precursor which is tagged with mannose-
6-phosphate and targeted to the endocytic pathway; in the early
endosomes precursor GILT is cleaved to a 30 kDa mature form
which resides in the late endosomes and lysosomes (8). GILT
is constitutively expressed by antigen-presenting cells (APCs).
Unlike other members of the MHC class II-restricted antigen pro-
cessing pathway, GILT expression is not regulated by the MHC
class II transactivator (CIITA); however, GILT expression is regu-
lated by the transcription factor STAT1 and induced by IFN-γ (9).
The diverse biological roles of GILT have recently been reviewed
(10, 11). This review will focus on the role of GILT in altering the
MHC class II peptidome, subsequent effects on T cell develop-
ment, tolerance, and autoimmunity, and emerging roles in cancer
and infection.
GILT ALTERS THE MHC CLASS II PEPTIDOME
The reductase function of GILT provides a critical role in
MHC class II-restricted processing. Studies investigating the
GILT dependency of MHC class II-restricted T cell epitopes
have demonstrated epitopes that are dependent and inde-
pendent of GILT expression for presentation. GILT-dependent
class II epitopes have been identified from multiple disulfide
bond-containing antigens, including the model antigen hen egg
lysozyme (6), melanocyte differentiation antigens tyrosinase and
tyrosinase-related protein 1 (TRP1) (4, 12), autoantigen myelin
oligodendrocyte glycoprotein (MOG) (13),viral glycoprotein (14),
and dust mite allergen Der p 1 (15) (Table 1). The reductase activ-
ity of GILT is essential for its function in MHC class II-restricted
processing, as mutation of the reductase active site cysteines results
in the inability to present a GILT-dependent hen egg lysozyme
epitope (16). GILT dependence is not specifically correlated with
the presence or proximity of disulfide bonds in the epitope, as
two hen egg lysozyme epitopes involving a disulfide bond are
GILT-independent (6). Rather, GILT dependence is thought to
depend on whether the epitope requires reduction to be exposed
for MHC class II binding. Mapping these peptide epitopes to the
tertiary structure of the intact, folded protein reveals that GILT-
dependent epitopes tend to be buried and, thus, are likely to require
reduction to be exposed for MHC class II binding. In contrast,
GILT-independent epitopes tend to be surface exposed (6, 17), sug-
gesting that these epitopes are available for MHC class II binding
in an acidic pH with proteolytic digestion, but without disulfide
bond reduction.
Mass spectrometric analysis of the MHC class II bound pep-
tides from resting murine splenocytes shows that at steady state
the majority of MHC class II bound self peptides are the same in
GILT-expressing and GILT-deficient splenocytes (18). This study
also reveals that 5.5% of peptides are at least 10-fold overrepre-
sented from GILT−/− splenocytes with 2% being uniquely pre-
sented by GILT−/− splenocytes (Table 1). We term these epitopes,
which are presented more efficiently in the absence of GILT, GILT-
prevented epitopes. The GILT-prevented epitopes in this study
were almost exclusively derived from the N- and C-termini which
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Hastings GILT in CD4+ T cell-mediated immunity
Table 1 | Examples of GILT-dependent, GILT-independent, and GILT-prevented epitopes.
GILT-dependent (4, 6, 12–15) GILT-independent (4, 6, 7) GILT-prevented (18)
Model antigens Hen egg lysozyme 74–88 Hen egg lysozyme 20–35
Hen egg lysozyme 46–61 Hen egg lysozyme 30-53
Self antigens Cysteinylated human IgG κ 188–203 Human IgG κ 145–159 Murine iroquois homeodomain protein 408–416
Rat myelin oligodendrocyte
glycoprotein 35–55
Murine lemur tyrosine kinase 3 1080–1103
Murine synapse defective 1, Rho
GTPase, homolog 2 1–16
Murine membrane associated guanylate kinase, WW,
and PDZ domain containing 1 44–67
Murine transmembrane protein 131 130–147
Murine short stature homeobox 2 91–99
Murine clathrin heavy chain linker domain containing 1
138–152
Murine DEAH (Asp-Glu-Ala-His) box polypeptide 9
1253–1264
Murine centrosomal protein 68 15–92
Murine cyclin B1 68–75
Self and tumor
antigens
Human tyrosinase 56-70; murine
tyrosinase-related protein 1 109–130
Viral antigens HIV-1 gp120 envelope protein 203–212 Influenza hemagglutinin 107–119
Allergens Dust mite Der p 1 110–131
typically lack structural constraints, suggesting that these regions
are readily available for MHC class II binding without reduc-
tion. Following disulfide bond reduction by GILT, new regions
of the protein become exposed and these GILT-prevented epi-
topes are presented on MHC class II to a much lesser degree or are
not observed. Table 1 summarizes examples of GILT-dependent,
GILT-independent, and GILT-prevented epitopes.
Thus, reduction by GILT alters the epitopes available for MHC
class II-restricted presentation, such that there are three subsets of
epitopes: (1) GILT-independent epitopes, which are presented by
both GILT-expressing and GILT-deficient APCs and may be the
largest subset, (2) GILT-dependent epitopes which require reduc-
tion in order to be presented efficiently, and (3) GILT-prevented
epitopes which are more likely to be presented in the absence of
GILT. It remains to be determined whether these three epitope
subsets are generated in response to a particular immune insult
and what percentage of immunodominant epitopes fall into each
of these categories.
GILT IN CD4+ T CELL DEVELOPMENT, TOLERANCE, AND
AUTOIMMUNITY
We have investigated the role of GILT in modulating CD4+ T cell
development, tolerance, and autoimmunity to a GILT-dependent
epitope of the autoantigen TRP1 using the TRP1-specific T cell
receptor (TCR) transgenic (TRP1Tg) mouse strain (Table 1).
TRP1, as well as tyrosinase, TRP2, and gp100, are melanocyte dif-
ferentiation antigens that are clinically relevant antigens in both
autoimmune vitiligo and melanoma. Vitiligo is an autoimmune
disease that results in the destruction of melanocytes, the pig-
ment producing cells in the skin. Although the immunopathologic
mechanism is not precisely known, lesional CD4+ T cells with a
Th17 phenotype, melanocyte-specific CD8+ T cells, and defects
in regulatory T (Treg) cells are found in vitiligo patients (19–
23). TRP1-specific CD4+ T cells in this mouse strain mediate
fur depigmentation (12, 24). An advantage of this model is that T
cells recognize a naturally occurring epitope of a clinically relevant,
skin-restricted autoantigen expressed in its native genetic context.
Thus, the TRP1Tg mouse strain is a useful model for the study
of development of autoreactive T cells and initiation of CD4+ T
cell-mediated autoimmune responses in the skin. However, since
TRP1-specific CD4+ T cells have not been identified as pathologic
in human vitiligo, this model may not accurately represent human
vitiligo, but rather serves as a model of CD4+ T cell-mediated
cutaneous autoimmunity.
Factors that control presentation of the MHC class II-restricted
peptidome have the potential to shape the thymic selection. Cor-
tical thymic epithelial cells present self peptide:MHC complexes
to CD4+ CD8+ double-positive thymocytes (25–27). Low avidity
interaction of the TCR with self peptide:MHC complexes provides
a survival signal termed positive selection and leads to downreg-
ulation of the unused coreceptor. Due to expression of peripheral
tissue-specific self antigens in medullary thymic epithelial cells
(mTECs), the thymic medulla is the primary site of negative selec-
tion, whereby thymocytes that bind self peptide:MHC complexes
with high avidity die by apoptosis (28, 29). Autoimmune regulator
(Aire) is a transcriptional regulator which permits the expression
of tissue-restricted antigens in mTECs (30). In addition to being
a reservoir of peripheral tissue-specific antigens, recent studies
have demonstrated that mTECs have the ability to present self
antigens and contribute to negative selection (31). Dependent on
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Hastings GILT in CD4+ T cell-mediated immunity
antigen expression by mTECs, thymic dendritic cells (DCs) serve
a major role in antigen presentation and negative selection (32).
Autoreactive T cells that escape negative selection may differentiate
into regulatory T cells in the thymus or be controlled by periph-
eral tolerance mechanisms (33–35). Thus, MHC class II-restricted
presentation plays a critical role in T cell development.
In the thymus of RAG1−/−TRP1Tg mice, CD4+ single-positive
TRP1-specific thymocytes do not develop, indicating that thymo-
cytes specific for the self antigen undergo deletion (Figure 1)
(24). In GILT−/−RAG1−/−TRP1Tg mice, an increased percent-
age of CD4+ single-positive TRP1-specific thymocytes develop,
demonstrating that GILT is required for thymic deletion of
TRP1-specific thymocytes. A similar percentage of CD4+ single-
positive TRP1-specific thymocytes develop in TRP1-deficient
(Ag−) RAG1−/−TRP1Tg mice as in GILT−/−RAG1−/−TRP1Tg
mice, indicating that the absence of TRP1 and GILT have a similar
effect on thymic deletion (Figure 1). These studies indicate that
GILT plays an important function in the thymic selection of CD4+
T cells specific for GILT-dependent epitopes, suggesting that GILT
has an active role in antigen processing by thymic APCs involved
in negative selection, including mTECs and thymic DCs.
In the periphery of RAG1−/−TRP1Tg mice, CD4+Vβ14+
TRP1-specific T cells develop in the absence of GILT or
TRP1; however, there is a reduced percentage of TRP1-specific
T cells in the lymph nodes of GILT−/−RAG1−/−TRP1Tg
mice (Figure 1) (24). Although TRP1-specific T cells in
GILT−/−RAG1−/−TRP1Tg mice escape thymic deletion, these
T cells are tolerant, as GILT−/−RAG1−/−TRP1Tg mice do
not develop vitiligo (Figure 1). This phenotype is not due
to inefficient presentation of GILT-dependent antigens in the
periphery, because T cells from GILT−/−RAG1−/−TRP1Tg mice
do not induce autoimmunity when transferred into GILT-
expressing recipients (Figure 1). A portion of the T cells in
GILT−/−RAG1−/−TRP1Tg mice are antigen-experienced with a
CD62L−CD44+ effector memory phenotype (Figure 1). TRP1-
specific T cells from GILT−/−RAG1−/−TRP1Tg mice exhibit
diminished IL-2 production after in vitro antigen exposure and
diminished production of IL-2 and IFN-γ after in vivo anti-
gen exposure (24). GILT−/−RAG1−/−TRP1Tg mice have a four-
fold increased percentage of Treg cells compared to Ag-TRP1Tg
mice, with Treg cells composing one-third of the TRP1-specific
T cells in the lymph node (Figure 1) (24). T cell tolerance in
FIGURE 1 | GILT in tolerance and autoimmunity. Schematic representation
of flow cytometry, phenotype, and adoptive transfer results in the TRP1Tg
mouse strains. Staining of thymocytes is shown in a forward scatter and side
scatter gate with dead cell exclusion. Staining of lymph node cells is shown
gated on Vβ14+CD4+ TRP1-specific T cells. (From top to bottom) in
RAG1−/−TRP1Tg mice, TRP1-specific T cells undergo thymic deletion (24). In
the absence of GILT or absence of TRP1 antigen (Ag−), there is a similar
percentage of CD4+ single-positive thymocytes (24). Although Vβ14+CD4+
TRP1-specific T cells are present in the periphery of GILT−/−RAG1−/−TRP1Tg
mice and some have a CD62L−CD44+ effector memory phenotype, these
mice do not develop vitiligo (24). There is an increased percentage of Treg
cells in GILT−/−RAG1−/−TRP1Tg mice compared to Ag-RAG1−/−TRP1Tg mice
(24). Tolerance is partially due to Treg cells, as adoptive transfer of Treg
cell-depleted, but not total, CD4+ T cells from GILT−/−RAG1−/−TRP1Tg mice
induces mild vitiligo in recipients (24). Ag-RAG1−/−TRP1Tg mice lack TRP1,
which is involved in melanin pigment synthesis, and, thus, have a lighter coat
color. In Ag-RAG1−/−TRP1Tg mice, all TRP1-specific T cells are naïve and
capable of inducing vitiligo following adoptive transfer into GILT+/+ recipients
(12). The onset of vitiligo is delayed and the severity is reduced following
adoptive transfer into GILT−/− recipients (12). In RAG-expressing TRP1Tg mice,
TRP1-specific T cells escape thymic deletion, populate the periphery and
induce spontaneous vitiligo (12). In GILT−/−TRP1Tg mice, there are increased
TRP1-specific T cells in the thymus and periphery, but fewer TRP1-specific T
cells with an effector memory phenotype and a delayed onset of vitiligo (12).
There is no difference in the percentage of TRP1-specific Treg cells between
TRP1Tg and GILT−/−TRP1Tg mice on the RAG-sufficient background (12).
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GILT−/−RAG1−/−TRP1Tg mice is partially mediated by Treg cells,
as adoptive transfer of Treg cell-depleted CD4+ T cells, but not
total CD4+ T cells, induces mild vitiligo in recipients (Figure 1).
In comparison, TRP1Tg mice on the RAG1−/− background do not
develop spontaneous autoimmunity, because TRP1-specific T cells
are deleted in the thymus (Figure 1). Ag-RAG1−/−TRP1Tg mice
do not develop vitiligo because they do not express the autoantigen
recognized by the transgenic T cells, although naïve T cells from
these mice cause rapid, severe vitiligo following adoptive transfer
into GILT and TRP1-expressing mice (Figure 1).
The source of the increased Treg cells, that are found
in GILT−/−RAG1−/−TRP1Tg mice compared to Ag-RAG1−/−
TRP1Tg mice and contribute to tolerance and prevention of
vitiligo, remains to be determined. Increased Treg cells may result
from intrathymic development of natural Treg cells, as an inter-
mediate avidity interaction between the TCR on the thymocyte
and peptide:MHC complexes on the thymic APCs is thought to
promote natural Treg development (31, 36). In the absence of
GILT, fewer TRP1 peptide:MHC complexes on thymic APCs may
shift the fate of TRP1-specific thymocytes from negative selec-
tion to natural Treg cell development. Alternatively, Treg cells can
be induced in the periphery following suboptimal antigen stim-
ulation (37, 38). GILT-deficient peripheral APCs are capable of
low level presentation of TRP1 (12), and this suboptimal presen-
tation may induce TRP1-specific T cells to undergo peripheral
conversion into Treg cells. It remains to be determined whether
GILT plays a direct role in the generation of TRP1-specific Treg
cells or whether other factors, such as expression of the autoanti-
gen TRP1, are sufficient. In addition, other tolerance mechanisms
likely limit the autoreactivity of TRP1-specific T cells that develop
in GILT−/−RAG1−/−TRP1Tg mice.
The phenotype of the TRP1Tg mice on the RAG-expressing
background differs (12). In RAG-expressing TRP1Tg mice, autore-
active TRP1-specific T cells escape thymic deletion, populate the
periphery, and induce vitiligo (12). This difference is likely due
to the expression of endogenous TCRs. Although the transgenic
TCR Vβ14 chain is the most frequent TCR in RAG1+/+TRP1Tg
mice, a diverse array of TCR Vα and Vβ chains are expressed (12).
These endogenous TCRs likely rescue autoreactive T cells from
thymic deletion as in other TCR transgenic models where autore-
active T cells are deleted on the RAG1−/− background but escape
thymic deletion in RAG-expressing mice or with expression of two
TCR transgenes on the RAG1−/− background (39, 40). Further-
more, effector function via the autoreactive TCR can be induced
through activation of the second TCR (40, 41).
In RAG-expressing GILT−/−TRP1Tg mice, an increased per-
centage of TRP1-specific T cells is found in the thymus and
periphery, suggesting that, as on the RAG1−/− background, dele-
tion of thymocytes recognizing a GILT-dependent epitope is less
efficient in the absence of GILT (Figure 1). In GILT−/− compared
to GILT-expressing RAG1+/+TRP1Tg mice, the median onset of
spontaneous vitiligo is delayed by 7 weeks (12). These mice have
a similar small percentage of TRP1-specific Treg cells, so Treg
cells do not account for the difference in TRP1-specific T cells
or disease onset (Figure 1). This result suggests that on the RAG-
expressing background GILT expression does not alter Treg cell
development. In the presence of GILT and following the onset of
vitiligo there is an increased percentage of TRP1-specific T cells
with an effector memory phenotype (12). Adoptive transfer of
naïve, TRP1-specific T cells from Ag-RAG1−/−TRP1Tg mice into
GILT-deficient and GILT-expressing recipients demonstrates that
GILT expression in the peripheral APCs of the recipient increases
the severity and accelerates the onset of vitiligo (12). Thus, in the
RAG-expressing TRP1Tg model, GILT improves the MHC class
II-restricted processing and presentation of TRP1 for enhanced
activation of autoreactive T cells and an accelerated onset of
vitiligo.
Multiple sclerosis is an autoimmune disease of the central
nervous system that results in multifocal areas of demyelination
with loss of oligodendrocytes and astroglial scarring. Bergman
et al. investigated the role of GILT in MOG-induced experimental
autoimmune encephalomyelitis (EAE), a mouse model of multi-
ple sclerosis (13). Immunization of wild-type mice with rat MOG
protein results in EAE that is CD4+ T cell-mediated and is B-cell-
independent. MOG contains a disulfide bond between cysteine
residues 24 and 98. GILT−/− splenocytes are unable to process rat
MOG protein and present MOG35–55, indicating that MOG35–55
is a GILT-dependent epitope (Table 1). Whereas MOG35–55 is the
exclusive encephalitogenic epitope produced by rat MOG protein-
induced EAE in wild-type mice, lymph node cells from GILT−/−
mice immunized with rat MOG protein proliferate in response
to several overlapping MOG peptides (MOG67–87, MOG85–105,
MOG104–177), but not MOG35–55, indicating that GILT alters the
peptides presented and the immunodominant epitopes. GILT−/−
mice are resistant to EAE induced by MOG35–55 peptide, which
is likely due to the inability of GILT−/− APCs to process endoge-
nous MOG protein to present the MOG35–55 epitope. However,
GILT−/−mice develop more severe disease compared to wild-type
mice after injection with the extracellular domain of rat MOG pro-
tein. This unanticipated finding is due to a switch in the pathogenic
mechanism from T cell-mediated autoimmunity in wild-type mice
to B-cell-mediated disease in GILT−/−mice. GILT−/−mice immu-
nized with MOG protein generate pathogenic antibodies which
bind oligodendrocytes and transfer EAE. These studies indicate
that changes in the MHC class II-restricted peptidome by GILT can
have a profound impact on the pathogenic mechanism and devel-
opment of autoimmunity. As many other autoantigens contain
disulfide bonds, e.g., TRP2, gp100, types VII and XVII collagen,
insulin, glutamic acid decarboxylase, and thyroid-stimulating hor-
mone receptor (5, 42–49), GILT is likely to alter the MHC class
II-restricted epitopes that are presented and the pathogenesis of
other autoimmune diseases.
GILT AND ANTI-TUMOR IMMUNITY
MHC class II-restricted antigen processing and presentation by
cancer cells may influence anti-tumor T cell responses and patient
outcome. Diffuse large B-cell lymphoma (DLBCL) is the most
common form of aggressive non-Hodgkin lymphoma, and low
MHC class II expression is known to be associated with poor sur-
vival in DLBCL (50). In this Research Topic, we present the first
evidence of the clinical significance of GILT expression (51). In
each of four independent gene expression profiling cohorts with a
total of 585 DLBCL patients, low GILT mRNA expression is signif-
icantly associated with poor overall survival. Low GILT expression
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is not associated with low expression of the MHC class II gene
HLA-DRA, as might be expected since GILT expression is not
regulated by CIITA. Low HLA-DRA expression is only associated
with poor survival in one of four cohorts, suggesting that GILT is
a better predictor of survival than HLA-DRA. Furthermore, the
association of low GILT mRNA expression with poor survival is
independent of established clinical and molecular prognostic fac-
tors. Immunohistochemical analysis of GILT protein expression
in 96 DLBCL tumor specimens demonstrates variation in GILT
expression within tumor cells with uniformly high GILT expres-
sion in tumor-infiltrating APCs, suggesting that GILT expression
is lost in tumor cells as opposed to a germline polymorphism
affecting GILT expression in all cell types. The loss of GILT expres-
sion in DLBCL tumor cells is anticipated to result in diminished
processing and presentation of GILT-dependent epitopes and may
represent a mechanism of immune evasion. Alternatively, GILT
may alter tumorigenesis through modification of the tumor cell
redox status, growth rate or function of an oncoprotein. These
findings underscore a role for GILT in patient outcome in DBLCL.
Further investigation is warranted to determine the mechanism of
GILT in lymphoma survival.
MHC class II-expressing melanoma cells are capable of pre-
senting endogenous melanoma antigens and have the potential
to stimulate anti-tumor T cell responses (52–55). While defects
in MHC class I-restricted processing and presentation have been
identified in melanoma and may contribute to immune evasion
(56–59), the roles of GILT and the MHC class II pathway are
relatively underexplored in melanoma despite their potential to
alter immune recognition. Unlike in DLBCL where low MHC
class II expression is associated with poor survival, in melanoma
ectopic MHC class II expression is associated with increased depth
of primary melanoma, poorer survival in primary melanoma,
and metastatic disease (60). One potential explanation for this
apparent paradox is that melanoma cells may have a defect in
the expression of a component of the MHC class II processing
pathway, such as GILT. Aberrant expression of MHC class II in
melanoma is due to expression of CIITA resulting from activation
of the B-cell-specific CIITA promoter III and the IFN-γ-inducible
CIITA promoter IV (61, 62). The mechanism of CIITA induction
in melanoma is unknown, but MHC class II expression paral-
lels the expression of chemokines CXCL-1 and CXCL-8 and the
nuclear expression of NFκB p50 subunit, which are associated with
tumor invasiveness and poor prognosis in melanoma (63). Aber-
rant expression of MHC class II driven by CIITA expression is
not anticipated to induce GILT expression (9). In support of this
possibility a study of sixteen human melanoma cell lines demon-
strated that MHC class II-expressing melanoma cells lack GILT
expression and are unable to present an MHC class II-restricted
epitope derived from the endogenous melanoma antigen tyrosi-
nase (4) (Table 1). Transfection with GILT enhances presentation
of the endogenous tyrosinase epitope. This study suggests that
MHC class II expression by melanoma cells in the absence of GILT
may be a mechanism of immune evasion, as GILT-deficient, MHC
class II-expressing melanoma cells may be unable to generate the
GILT-dependent epitopes presented by professional APCs which
activate the T cell repertoire. Furthermore, multiple melanoma
antigens, including tyrosinase, TRP1, TRP2, and gp100, contain
disulfide bonds and likely contain GILT-dependent epitopes (44,
45, 48). In addition to tyrosinase, a naturally occurring epitope
from TRP1 is GILT-dependent (Table 1) (12). Further studies are
needed to determine the clinical relevance of GILT in melanoma
pathogenesis and patient survival.
GILT AND ANTI-VIRAL IMMUNE RESPONSES
The role of GILT in MHC class II-restricted presentation of viral
proteins has been investigated. MHC class II-restricted presen-
tation of an epitope from the human immunodeficiency virus
(HIV)-1 envelope protein gp120, which is located at the base of
the V1/V2 loops and encompasses a cysteine residue involved in
a disulfide bond, is GILT-dependent, and an adjacent epitope in
HIV-1 gp120, which includes a downstream disulfide-bonded cys-
teine residue, is partially dependent on GILT (Table 1) (14). In
contrast, MHC class II-restricted presentation of the site 1 epi-
tope of the influenza hemagglutinin major subunit, which requires
reduction, is GILT-independent (Table 1) (7). The role of GILT
in anti-pathogen CD4+ T cell-mediated responses remains to be
studied. In addition to a role in MHC class II-restricted presen-
tation, GILT facilitates cross-presentation of exogenous viral anti-
gens containing disulfide bonds on MHC class I for recognition
by CD8+ T cells (17). GILT is required for the cross-presentation
of a herpes simplex virus-1 (HSV-1) glycoprotein B (gB) epitope
involving residues 498–505 from exogenous recombinant gB or
HSV-1-infected cell debris, but not for cross-presentation of an
epitope from an HSV-1 cytosolic protein or direct MHC class I-
restricted presentation of the gB epitope in infected DCs. GILT is
also required for cross-priming of gB-specific CD8+ T cells in vivo,
as a smaller percentage of gB-specific CD8+ T cells are generated in
HSV-1 infected GILT−/− mice compared to wild-type mice. Sim-
ilarly, GILT is essential for cross-priming of CD8+ T cells specific
for epitopes from the hemagglutinin and neuraminidase enve-
lope proteins of influenza virus. Thus, in addition to a role in
MHC class II-restricted presentation for stimulation of CD4+ T
cell responses, GILT plays a role in cross-presentation of exoge-
nous antigens on MHC class I and cross-priming of CD8+ T cells,
which is important in both viral infection and cancer. It remains
to be determined whether alteration of CD4+ and CD8+ T cell
epitopes by GILT impacts the overall host response to infection.
CONCLUSION AND FUTURE DIRECTIONS
Gamma-interferon-inducible lysosomal thiol reductase is a unique
reductase in the endocytic compartment which alters the MHC
class II peptidome. Certain epitopes require GILT for efficient pre-
sentation, others are presented independent of GILT, and some are
presented more efficiently in the absence of GILT. GILT-mediated
fine changes in the peptide repertoire presented on MHC class II
modify thymic selection and shape the T cell repertoire in such a
way that influences the pathogenesis of autoimmune disease. Addi-
tionally, low GILT expression in tumor cells is associated with poor
survival in lymphoma, possibly through loss of immune-mediated
destruction. Further investigation is needed to determine the pre-
cise mechanisms of GILT’s role in cancer pathogenesis and survival
as well as other aspects of CD4+ T cell-mediated immunity,
especially in regard to anti-pathogen immune responses. Future
studies will elucidate the potential role of GILT as a biomarker for
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predicting disease outcome and as a therapeutic target to suppress
autoimmune disease or improve anti-tumor immunity.
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